Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
about
SMC complexes link gene expression and genome architectureControversies and challenges in research on urogenital schistosomiasis-associated bladder cancerCohesin mutations in myeloid malignancies: underlying mechanismsDose-dependent role of the cohesin complex in normal and malignant hematopoiesis.Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.Genetic and Epigenetic Alterations in Bladder CancerInvasive Bladder Cancer: Genomic Insights and Therapeutic PromisePatient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function.Enhanced copy number variants detection from whole-exome sequencing data using EXCAVATOR2Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.Identification of ALK gene alterations in urothelial carcinoma.Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibitionGenetic alterations of the cohesin complex genes in myeloid malignancies.Cohesin gene mutations in tumorigenesis: from discovery to clinical significanceSTAG2 promotes error correction in mitosis by regulating kinetochore-microtubule attachments.Meiotic cohesin STAG3 is required for chromosome axis formation and sister chromatid cohesionSororin pre-mRNA splicing is required for proper sister chromatid cohesion in human cells.Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated geneHRAS mutations are frequent in inverted urothelial neoplasms.Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.NOTCH pathway inactivation promotes bladder cancer progressionIntegrative epigenomic analysis of differential DNA methylation in urothelial carcinoma.The contribution of cohesin-SA1 to gene expression and chromatin architecture in two murine tissues.Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.Molecular biology of bladder cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasmsLeukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas.The three-dimensional cancer genome.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
P2860
Q26826804-5FF6F764-811D-4A8A-A696-C8AB4971F6E3Q27008499-9C90010E-FC33-42B2-8F85-8C2BCB40C789Q27022740-50FB7B36-FD8D-4D3D-B16C-CA534835583CQ27308738-C8E7DAD9-91AE-44B0-974C-FE92C754F7D1Q27853334-9B94C895-6DF4-426A-BB0E-509567D127DFQ28074732-D1ED626E-E391-4849-9954-361640DD7C48Q28088334-2D217F8E-A387-448A-82FE-8BA0C7A45C36Q30279180-008FA2B6-4159-4983-A891-98DC8F48330FQ30667509-1094C7AF-7AF3-46E5-ABFE-F91FDB79F521Q31120762-945F67C8-2563-4208-BA00-0328C5939EB7Q33568623-23310924-C788-4223-876B-2B28DD9CCA2DQ33583057-52F55FCB-9C0F-4D2F-96AD-384A70B8B8DAQ33881163-F9D77585-C774-4B0F-A069-3B2358EC4652Q33989002-FE2B978A-29F3-469A-B848-4DDC528624AEQ34034221-613EF611-39C1-4979-9435-70AF6BE9D86BQ34170374-6CCD97F9-6FDC-4232-9A66-DA2EAF5A9F59Q34179964-F0D549C2-9793-4F7F-8701-E0A1EFBB8BC9Q34264526-E0C6526F-77D8-4872-9C50-6F2E2D03525EQ34343224-C2092803-CC3A-4FCA-B49E-30DFA0DDC31AQ34343252-940679BA-BDEA-43DC-A155-C2A8837CE1EDQ34469971-677220CC-EAED-4D16-A333-5BC598FB778AQ34478820-9BE65572-ED7F-4CA7-8DC3-B49ED7E85C2DQ34563001-CB82837D-7746-42FB-ADA5-468A384A3259Q34691553-97BA5E7B-F739-4246-BEAD-EBCE02DA25A2Q35034441-485960D9-F9B8-4C83-99D3-625CAEC0CF08Q35056671-E081D430-99A6-46DE-B0BF-656DDB172B93Q35215704-E4B5EBED-C8B2-487F-A0CE-6495FF87CAC5Q35237045-D9802C06-1A3D-4037-A819-E3213F22544CQ35250650-F7E9056D-3412-4193-9510-6C5BA76B9362Q35266400-E3964408-F725-4E94-B96A-C9B81A424014Q35638497-705DCAE9-B176-417D-9C63-15A7F257EAC5Q35922216-AA397889-10BD-4DD3-9CFD-CB29967D4DEFQ36054919-7F1D6D90-61C9-4BA8-9EEB-FA1FA6D65784Q36180677-B69C9B3D-A930-477C-A254-F579D028F81EQ36352394-D9AB1573-4FC9-4547-9435-6F20B9A0A8F9Q36506766-24E3EC64-5A83-49C2-A0AF-05187A9E6158Q36514637-05B1658E-0026-4037-97A8-C2AC24FEEECAQ36545314-AA2A68B7-4048-40D4-9553-B4273F0C83A2Q36936249-5981E846-5F56-4A82-8CE5-5BC3A3009EE3Q37053820-A2ECDCF1-F7C9-45F3-BA4D-39BFED2C4957
P2860
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@en
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@nl
type
label
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@en
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@nl
prefLabel
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@en
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
@en
P2093
Alfredo Carrato
Ana Sagrera
Cristina Balbás-Martínez
Eleonora Lapi
Josep Lloreta
José A Lorente
Juan C Cigudosa
Julie Earl
Laia Richart
P2860
P2888
P304
P356
10.1038/NG.2799
P407
P50
P577
2013-10-13T00:00:00Z